Zhang Xuebao, Liu Chu, Li Kui, Wang Ke, Zhang Qiqiang, Cui Yuanshan
Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai.
Department of Urology Surgery, The People's Hospital of Yucheng, Yucheng.
Medicine (Baltimore). 2019 Feb;98(6):e14254. doi: 10.1097/MD.0000000000014254.
Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC).We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated.Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002).Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo.
考布他汀是第二代反义寡核苷酸（ASO），它可以降低簇集素的细胞水平，以增强化疗药物的细胞毒性作用。我们的研究评估了考布他汀在转移性去势抵抗性前列腺癌（mCRPC）患者中的疗效和安全性。我们进行了全面检索，以识别考布他汀治疗mCRPC的所有随机对照试验（RCT）。对检索到的研究的参考文献列表进行了调查。分析中使用了3篇共涉及1709例患者的出版物。我们发现，在比较中总生存期（OS）（P = 0.25）无统计学显著差异。安全性评估表明，考布他汀常与中性粒细胞减少（P < 0.001）、贫血（P < 0.001）、血小板减少（P < 0.001）和腹泻（P = 0.002）引起的并发症相关。我们的荟萃分析表明，考布他汀对改善mCRPC患者的OS无明显作用。与接受安慰剂治疗的患者相比，接受考布他汀治疗的患者不良反应更常见。
